PROFESSIONAL EDITION

The largest community of pharma leaders

XyloCor Therapeutics Names Alexander Gaidamaka, PhD, Senior Vice President of Technology, Manufacturing & Quality

PHILADELPHIA–()–XyloCor Therapeutics, a private clinical‑stage biopharmaceutical company focused on the development of gene therapy for unmet needs in cardiovascular disease, strengthens its leadership team with the appointment of Alexander Gaidamaka, PhD, as Senior Vice President of Technology, Manufacturing & Quality. Dr. Gaidamaka brings a wealth of product development, regulatory and manufacturing experience across multiple technology platforms and GMP quality design and operations from his tenures with Sanofi Group, AmpliPhi Biosciences, Personalized OncoTherapeutics Inc. and several other companies.

“At this critical time in our growth, we are excited to have Alexander join our team. His broad therapeutics experience from pre-clinical and clinical development through manufacturing processes will be invaluable to both our clinical and pre-clinical gene therapy programs,” said Al Gianchetti, President and Chief Executive Officer of XyloCor Therapeutics. “Quality manufacturing is imperative when developing gene therapies, and his insights and skillset, developed from experience both in the US and globally, will bring XyloCor Therapeutics one step closer to helping patients with refractory angina who currently have no treatment options.”

With more than 25 years of experience in the pharmaceutical industry, Dr. Gaidamaka previously served as Vice President of Chemistry, Manufacturing & Controls for AmpliPhi Biosciences where he led and defined CMC strategy and application, implemented GMP production of clinical trial material and completed several IND submissions to the U.S. Food and Drug Administration for clinical trials and compassionate use. As Chief Executive Officer and Chief Scientific Officer at Personalized OncoTherapeutics, he developed a scalable technology concept for a personalized therapeutic cancer vaccine platform and conducted early research studies within cross-functional international projects. As Director of Biologics Development at Merial (Sanofi) and Senior Manager of QC Immunochemistry at Sanofi Pasteur, he executed on a broad spectrum of tasks from development to product approval, manufacturing and all aspects of GMP quality systems.

Dr. Gaidamaka began his career in pharmaceuticals by developing a series of generic and brand medicines when serving as the Head of the Department of Immunopharmacology & Allergology at State Scientific Center of Drugs, Ukraine. He then founded Biopharm LLC (Ukraine) and served as Chief Executive Officer. He also served as a subject matter expert for biologics at Ukrainian Pharmacopeia Committee. He received his PhD in immunology and microbiology and a Doctor of Veterinary Medicine from Kharkov Veterinary Academy. He is also an author of 42 publications and holds two patents.

About XyloCor
XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. The Company’s lead product candidate, XC001, is in clinical development to investigate use for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. Co‑founded by Ronald Crystal, MD, and Todd Rosengart, MD, XyloCor has a licensing agreement with Weill Cornell Medicine for the worldwide rights to develop, manufacture and commercialize XC001. For more information, visit www.xylocor.com.​

Source

Recent Articles